0
0
New Oral Drug Offers Hope for Patients with Advanced Breast Cancer Resistant to Endocrine Therapy
On September 25, 2025, the U.S. Food and Drug Administration (FDA) granted approval to Eli Lilly’s oral estrogen receptor antagonist, imlunestrant (brand name Inluriyo), for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed following at least one line of endocrine therapy. This approval marks an important milestone in expanding treatment options for a specific genetic subtype of metastatic breast cancer, which historically presents significant treatment challenges.
Understanding Metastatic Breast Cancer and ESR1 Mutation
Metastatic breast cancer, often referred to as Stage IV breast cancer, occurs when cancer cells spread from the breast to other parts of the body such as bones, lungs, liver, or brain. The subtype targeted by Inluriyo is characterized by ER positivity and HER2 negativity, with mutations in the ESR1 gene, which codes for the estrogen receptor. These mutations can cause estrogen receptor overactivation, leading to uncontrolled tumor growth and resistance to standard hormone therapies.
Key Trial Data Supporting Approval
The FDA approval was based primarily on data from the phase 3 EMBER-3 trial, a late-stage clinical study evaluating the efficacy of Inluriyo versus standard endocrine therapies in patients with ESR1-mutated metastatic breast cancer. In this trial, Inluriyo demonstrated a 38% reduction in the risk of disease progression or death compared to standard therapies (hazard ratio approximately 0.62). Median progression-free survival (PFS) increased to 5.5 months for patients receiving Inluriyo, compared to 3.8 months for those on conventional treatment.
Adverse events were primarily mild to moderate (grade 1 or 2), including laboratory abnormalities such as lowered calcium levels, musculoskeletal pain, fatigue, diarrhea, and neutrophil count reductions. Notably, only 4.6% of patients discontinued treatment due to side effects, while dose adjustments were necessary in some cases. Importantly, safety labeling includes a caution about embryo-fetal toxicity, underscoring risks during pregnancy.
Expert Perspectives
Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, highlighted Inluriyo’s approval as an “important step toward advancing innovative, all-oral treatment approaches” in breast cancer that could improve patient quality of life by offering an alternative to injectable therapies.
Komal Jhaveri, clinical director of early drug development at Memorial Sloan Kettering Cancer Center and an investigator in the EMBER-3 trial, underscored the significance of Inluriyo for patients with ESR1 mutations: “These mutations often contribute to hormone therapy resistance, so having a targeted oral option that degrades estrogen receptors offers a meaningful alternative treatment choice for this patient group”.
Jean Sachs, CEO of Living Beyond Breast Cancer, emphasized patient impact: “Eligible patients will now have access to an additional treatment option, offering flexibility in daily life and renewed hope for the future”.
Context and Comparison to Existing Therapies
Until recently, treatment for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations relied mainly on injectable selective estrogen receptor degraders (SERDs) like fulvestrant. Fulvestrant, while effective, requires intramuscular administration and can present barriers such as clinic visits and injection-related discomfort.
Inluriyo belongs to the next generation of oral SERDs, offering easier administration and the potential for improved patient adherence. Several other oral SERDs are in development or undergoing regulatory review by companies such as Roche, AstraZeneca, and partnerships like Arvinas-Pfizer, aiming to expand treatment options for hormone-resistant breast cancer. Though promising, the overall impact of these new oral agents on broader breast cancer care remains to be fully defined. Some oncologists have noted “unknowns” regarding long-term effectiveness and applicability in patients without ESR1 mutations.
Implications for Public Health and Patient Care
The FDA approval of Inluriyo illustrates progress in personalized cancer care by tailoring treatments to specific genetic mutations driving tumor growth. For patients with metastatic breast cancer who have experienced progression despite endocrine therapies, Inluriyo can offer a targeted approach that may improve disease control and quality of life.
Health care providers should consider genetic testing for ESR1 mutations in patients with advanced ER-positive, HER2-negative breast cancer to guide treatment decisions. The availability of a reliable companion diagnostic (Guardant360 CDx assay) authorized alongside Inluriyo facilitates identification of eligible patients.
Limitations and Counterarguments
While the EMBER-3 trial showed positive results, median progression-free survival improvements were modest, and the overall survival benefit remains to be established with longer follow-up. Additionally, the treatment’s high cost (approximately $22,500 per 28-day supply) may limit accessibility and affordability for some patients. As with all new therapies, ongoing post-marketing studies will be critical to confirm long-term safety and effectiveness and to evaluate combination strategies with other cancer drugs.
Practical Takeaways for Readers
For individuals living with metastatic breast cancer, this approval offers a new treatment option that is orally administered and specifically designed to target resistant cancer driven by ESR1 mutations. This development highlights the increasing role of genetic testing in cancer care and the shift toward personalized therapies that improve patient convenience and outcomes.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
